• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies

  • Print
  • Share
  • E-mail
-

Post-Approval Studies

  • In January 2005, the oversight responsibility of the Post-Approval Studies Program was transferred to the Division of Epidemiology (DEPI) of the Office of Surveillance and Biometrics (OSB)/Center for Devices and Radiological Health (CDRH).
  • The CDRH Post-Approval Studies Program encompasses design, tracking, oversight, and review responsibilities for studies mandated as a condition of approval of a premarket approval (PMA) application, protocol development product (PDP) application, or humanitarian device exemption (HDE) application. The program helps ensure that well-designed post-approval studies (PAS) are conducted effectively and efficiently and in the least burdensome manner.
  • CDRH has established an automated, internal tracking system that efficiently identifies the reporting status of active PAS studies ordered since January 1, 2005 based on study timelines incorporated in study protocols and agreed upon by the CDRH and applicants. This system represents CDRH's effort to ensure that all PAS commitments are fulfilled in a timely manner.
  • In addition, CDRH launched this publicly available webpage to keep all stakeholders informed of the progress of each PAS. The webpage displays general information regarding each PAS, as well as the overall study status (based on protocol-driven timelines and the adequacy of the data) and the applicant's reporting status for each submission due.

Links

Contact Information

Julie Unger
Project Manager, Post-Approval Studies Program
Food and Drug Administration
10903 New Hampshire Ave
WO66-4206v Silver Spring, MD
20993-0002

Phone: (301) 796-6134
Fax: (301) 847-8140
julie.unger@fda.hhs.gov

Show All Studies
Suggest Enhancement / Report Issue | Export to ExcelExport to Excel
General
Application Number P030002 S027
Current Protocol Accepted 06/27/2014
Study Name New Enrollment Study
Study Status Progress Adequate
General Study Protocol Parameters
Study Design Prospective Cohort Study
Study involve follow-up of premarket cohort (Y/N) No
Data Source New Data Collection
Comparison Group No Control
Analysis Type Descriptive
Study Population Adult: >21
Detailed Study Protocol Parameters
Study Design Description The objective of this post approval safety study is to evaluate the incidence of

IOL vaulting   show the rest ...
Study Population Description All subjects who meet eligibility criteria will be consecutively offered enrollment

into the trial until a   show the rest ...
Sample Size This study will enroll up to approximately 600 eyes at a minimum of 30 and   show the rest ...
Data Collection The study endpoint is the incidence of clinically significant IOL vaulting (ie,

position change such as   show the rest ...
Followup Visits and Length of Followup The duration of the study, including time to recruit all subjects, will be up to   show the rest ...


New Enrollment Study Schedule

Report Schedule
Report
Date Due
FDA Receipt
Date
Reporting Status
six month report 11/18/2013 01/28/2014 Overdue/Received
one year report 05/20/2014 06/25/2014 Overdue/Received
18 month report 11/18/2014    
two year report 05/20/2015    
30 month report 11/18/2015    
three year report 05/19/2016    
four year report 05/19/2017    
five year report 05/19/2018    

Show All Studies

-
-